DE69227500T2 - In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper - Google Patents

In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper

Info

Publication number
DE69227500T2
DE69227500T2 DE69227500T DE69227500T DE69227500T2 DE 69227500 T2 DE69227500 T2 DE 69227500T2 DE 69227500 T DE69227500 T DE 69227500T DE 69227500 T DE69227500 T DE 69227500T DE 69227500 T2 DE69227500 T2 DE 69227500T2
Authority
DE
Germany
Prior art keywords
hiv
infection
monoclonal antibodies
protein
capacity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69227500T
Other languages
English (en)
Other versions
DE69227500D1 (de
Inventor
Tsuneya Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRD Pharmaceuticals Inc
Original Assignee
Nissin Shokuhin KK
Nissin Food Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissin Shokuhin KK, Nissin Food Products Co Ltd filed Critical Nissin Shokuhin KK
Application granted granted Critical
Publication of DE69227500D1 publication Critical patent/DE69227500D1/de
Publication of DE69227500T2 publication Critical patent/DE69227500T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
DE69227500T 1991-08-22 1992-08-24 In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper Expired - Fee Related DE69227500T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74856291A 1991-08-22 1991-08-22
PCT/US1992/007111 WO1993004090A1 (en) 1991-08-22 1992-08-24 Hiv immunotherapeutics

Publications (2)

Publication Number Publication Date
DE69227500D1 DE69227500D1 (de) 1998-12-10
DE69227500T2 true DE69227500T2 (de) 1999-04-15

Family

ID=25009973

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227500T Expired - Fee Related DE69227500T2 (de) 1991-08-22 1992-08-24 In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper

Country Status (9)

Country Link
EP (1) EP0554446B1 (de)
JP (1) JP2888980B2 (de)
KR (1) KR100251823B1 (de)
AT (1) ATE173024T1 (de)
AU (1) AU659677B2 (de)
CA (1) CA2094611C (de)
DE (1) DE69227500T2 (de)
RU (1) RU2128222C1 (de)
WO (1) WO1993004090A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330280T2 (de) * 1992-08-24 2001-12-06 Nissin Food Products Ltd Immuntherapeutika gegen hiv
KR100337069B1 (ko) * 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
CA2170034C (en) * 1993-08-24 2005-03-15 Joseph William Harris Recombinant humanized anti-human immunodeficiency virus antibody
US5618922A (en) * 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2358915C (en) 1998-12-31 2010-06-01 Chiron Corporation Modified hiv env polypeptides
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
ATE369427T1 (de) 2001-03-22 2007-08-15 Us Health Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
EP2412242A3 (de) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polypeptide vom HIV-Typ C codierende Polynucleotide, Polypeptide und deren Verwendung
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295803B1 (de) * 1987-05-29 1993-11-03 Shuzo Matsushita Monoklonale Antikörper
DE3853779T2 (de) * 1987-05-29 1995-09-07 Tanox Biosystems Inc Hiv-1 neutralisierende monoklonale antikörper.
EP0339504A3 (de) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
AU6036690A (en) * 1989-06-05 1991-01-07 Helen F. Carson Human monoclonal antibodies to hiv-1mn gp 120
JP2989862B2 (ja) * 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体

Also Published As

Publication number Publication date
WO1993004090A1 (en) 1993-03-04
JPH06503970A (ja) 1994-05-12
KR100251823B1 (ko) 2000-04-15
EP0554446A1 (de) 1993-08-11
AU2568392A (en) 1993-03-16
EP0554446B1 (de) 1998-11-04
CA2094611A1 (en) 1993-02-23
EP0554446A4 (de) 1994-02-09
RU2128222C1 (ru) 1999-03-27
AU659677B2 (en) 1995-05-25
DE69227500D1 (de) 1998-12-10
CA2094611C (en) 2000-07-25
JP2888980B2 (ja) 1999-05-10
ATE173024T1 (de) 1998-11-15
KR930702509A (ko) 1993-09-09

Similar Documents

Publication Publication Date Title
DE69227500T2 (de) In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper
JPH06502539A (ja) Ｈｉｖ−１　ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体
AT398080B (de) Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel
DE3853779D1 (de) Hiv-1 neutralisierende monoklonale antikörper.
ATE238420T1 (de) Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus
US5854400A (en) Monoclonal antibodies which neutralize HIV-1 infection
RU93005284A (ru) Моноклональные антитела линии клеток, фармацевтические композиции, способы лечения, фрагмент антитела
US6132721A (en) Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
SE9000333D0 (sv) Monoklonal antikropp
KR0149848B1 (ko) Hiv에 특이한 모노클로날 항체 및 그 제조용 하이브리도마
AU8010791A (en) Hiv monoclonal antibody
US6124132A (en) Use of anti-HIV IGA antibodies for producing immunological protection against the human immunodeficiency virus
US6200575B1 (en) Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
ATE201698T1 (de) Immuntherapeutika gegen hiv
CN1172717C (zh) 一种治疗艾滋病的药物及其制备方法
RU94024562A (ru) Антитело, полинуклеотид, клетка, способ получения антитела
RU94046321A (ru) Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе
WO1988007376A1 (en) Remedy for viral diseases
KR100871455B1 (ko) Ｈｉｖ 바이러스에 대한 천연 항체
CA2079230A1 (en) Bcrf1 antagonists for treating epstein-barr virus infections
ATE102836T1 (de) Arzneimittel fuer die behandlung oder die verhuetung von infektionen mit hiv durch immunisierung, und verfahren zur herstellung.
WO2002026259A1 (fr) Medicament pour le traitement du sida et son procede de preparation
CA2046016A1 (en) Hiv monoclonal antibody

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SRD PHARMACEUTICALS,INC., WESTPORT, CONN., US

8339 Ceased/non-payment of the annual fee